ulcerdx.com
Metabolomic Technologies Inc.
http://www.ulcerdx.com/m_science.html
Core Scientific and Business Team. Research and Development Facilities. L NEWS / ARTICLES.
ulcerdx.com
Metabolomic Technologies Inc.
http://www.ulcerdx.com/p_otherproducts.html
Core Scientific and Business Team. Research and Development Facilities. MTI is also developing many other exciting and innovative products. BreastDx - Diagnostic for Breast Cancer. ProstateDx - Diagnostic for Prostate Cancer. CeliacDx - Diagnostic for Celiac Disease. ColitisDx - Diagnostic for Ulcerative Colitis. CrohnsDx - Diagnostic for Crohn's Disease. IBDDx - Diagnostic for IBD. LactoseDx - Diagnostic for Lactose Intolerance. RefluxDx - Diagnostic for Acid Reflux. L NEWS / ARTICLES.
ulcerdx.com
Metabolomic Technologies Inc.
http://www.ulcerdx.com/about_commercial.html
Core Scientific and Business Team. Research and Development Facilities. Emerging Biomarker Business Model. MTl's PolypDx test is well positioned for the ‘screening’ market, and its ColoDx test for the ‘diagnosis’ market. Discussions with potential partners indicate that MTI’s tests are also well-positioned to serve the downstream markets post diagnosis - often termed as ‘companion diagnostics’. The emerging biomarker value chain presents several revenue opportunities that MTI can enter. L NEWS / ARTICLES.
ulcerdx.com
Metabolomic Technologies Inc.
http://www.ulcerdx.com/about_people.html
Core Scientific and Business Team. Research and Development Facilities. CORE SCIENTIFIC AND BUSINESS TEAM. Richard N Fedorak, MD - President and Chief Medical Officer. Reg Joseph, BSc, MBA - Chief Executive Officer (on leave to AIHS). Haili Wang, MD - Vice President and Chief Scientific Officer. David Chang, MASc, PhD - Chief Operating Officer. Goncalo Goya, MSc, MBA - Vice President Commercial Operations. Lu Deng, PhD - Senior Scientist. Lu Deng completed her PhD in the Department of Chemistry at the Un...
ulcerdx.com
Metabolomic Technologies Inc.
http://www.ulcerdx.com/p_overview.html
Core Scientific and Business Team. Research and Development Facilities. Metabolomic Technologies Inc. (MTI) uses a new and emerging science known as metabolomics to detect differences in urine samples from people who have cancer adenomas (precancerous polyps) and normal people. MTI's diagnostics thus provide the potential for game-changing enhancements in the screening of patients for colorectal cancer and colonic polyps. There is absolutely no competition to MTI's PolypDx and ColoDx pr...
ulcerdx.com
Metabolomic Technologies Inc.
http://www.ulcerdx.com//SiteMap.html
Core Scientific and Business Team. Research and Development Facilities. Core Scientific and Business Team. Research and Development Facilities. L NEWS / ARTICLES.
ulcerdx.com
Metabolomic Technologies Inc.
http://www.ulcerdx.com/n_scientific.html
Core Scientific and Business Team. Research and Development Facilities. Consistency of Metabolite Determination from NMR Spectra over Time and Between Operators. V Tso, R Eisner, S Macleod, KP Ismond, RR Foshaug, H Wang, R Joseph, D Chang, N Taylor, RN Fedorak. Metabolomics: Open Access, 2015 Sept; 5(3):151. Budgeted transcript discovery: a framework for joint exploration and validation studies. S Khan, R Greiner. Bioinformatics and Biomedicine, 2014 IEEE International Conference Nov;188-91. Canadian Jou...
crohnsdx.com
Metabolomic Technologies Inc.
http://www.crohnsdx.com/about_people.html
Core Scientific and Business Team. Research and Development Facilities. CORE SCIENTIFIC AND BUSINESS TEAM. Richard N Fedorak, MD - President and Chief Medical Officer. Reg Joseph, BSc, MBA - Chief Executive Officer (on leave to AIHS). Haili Wang, MD - Vice President and Chief Scientific Officer. David Chang, MASc, PhD - Chief Operating Officer. Goncalo Goya, MSc, MBA - Vice President Commercial Operations. Lu Deng, PhD - Senior Scientist. Lu Deng completed her PhD in the Department of Chemistry at the Un...
crohnsdx.com
Metabolomic Technologies Inc.
http://www.crohnsdx.com/about_career_opportunities.html
Core Scientific and Business Team. Research and Development Facilities. We currently have no open job position at Metabolomic Technologies Inc. We thank you for your interest in working with us. L NEWS / ARTICLES.
crohnsdx.com
Metabolomic Technologies Inc.
http://www.crohnsdx.com/p_polydx.html
Core Scientific and Business Team. Research and Development Facilities. POLYPDX - DIAGNOSTIC FOR PRECANCEROUS ADENOMATOUS POLYPS. MTI's lead product is a unique diagnostic system that can detect colonic adenomatous polyps (the precursor to colorectal cancer) based on a unique "fingerprint" of metabolites from a urine test. Unlike fecal-based tests, MTI's urine-based PolypDx detects polyps before they become cancerous. Non-invasive and does not require any dietary restrictions or fecal collections.